Next Article in Journal
Macrophages and Cell-Cell Spread of HIV-1
Next Article in Special Issue
Cyclophilin Inhibitors as a Novel HCV Therapy
Previous Article in Journal
A VSV-G Pseudotyped Last Generation Lentiviral Vector Mediates High Level and Persistent Gene Transfer in Models of Airway Epithelium In Vitro and In Vivo
Previous Article in Special Issue
Targeting microRNA-122 to Treat Hepatitis C Virus Infection
Viruses 2010, 2(8), 1589-1602; doi:10.3390/v2081589

Interferon-λ in HCV Infection and Therapy  

Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA
* Author to whom correspondence should be addressed.
Received: 28 June 2010 / Accepted: 28 July 2010 / Published: 5 August 2010
(This article belongs to the Special Issue Antivirals Against Hepatitis C Virus)
View Full-Text   |   Download PDF [207 KB, uploaded 12 May 2015]   |   Browse Figures


Chronic infection with hepatitis C virus (HCV) is associated with significant liver disease and is therefore an important public health problem. The current standard-of-care therapy for chronic HCV infection consists of a combination of pegylated (PEG) interferon (IFN)-α and ribavirin. Although this therapy effectively generates a sustained viral response in approximately half of treated individuals, it is associated with significant hematological and neurological side effects. A new family of IFN-related proteins (IFN-λ1, 2, and 3; or alternately, IL-29, 28A, 28B, respectively) possesses properties that may make these cytokines superior to PEG-IFN-α for HCV therapy. Genetic studies have also implicated these proteins in both the natural and therapy-induced resolution of HCV infection. This review summarizes the basic aspects of IFN-λ biology, the potential role of these cytokines in HCV infection, and the outlook for their therapeutic application.
Keywords: IFN-λ; IL-28; IL-29; type III interferon; IL28B; IL-28Rα IFN-λ; IL-28; IL-29; type III interferon; IL28B; IL-28Rα
This is an open access article distributed under the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Pagliaccetti, N.E.; Robek, M.D. Interferon-λ in HCV Infection and Therapy  . Viruses 2010, 2, 1589-1602.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert